Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

John Payne Biography and Net Worth

Director of ZIVO Bioscience

Mr. Payne was the founder of Compassion-First Pet Hospitals, and served as President and CEO from 2014 until 2020. Compassion-First Pet Hospitals, now NVA Compassion-First, is a family of specialty and emergency veterinary hospitals located throughout the United States that is dedicated to changing the veterinary landscape and elevating patient outcomes. Mr. Payne currently serves as Vice Chairman of National Veterinary Associates, with which Compassion-First Pet Hospitals combined. Prior to founding Compassion-First, Mr. Payne served as a member of the Global Leadership Team for Mars Pet Care. He also served as President and CEO of Banfield Pet Hospitals and as President and General Manager of Bayer Healthcare’s North American Animal Health Division.

Mr. Payne currently serves as Chairman of the Board for American Humane and as Vice Chairman of the Board of Regents at Ross University School of Medicine and School of Veterinary Medicine. He served on the Board of Directors of Nexvet, a bioscience company located in Dublin, Ireland, through the company’s acquisition by Zoetis in 2018.

How old is John Bernard Payne?: Mr. Payne is currently 76 years old. There are 1 older executives and no younger executives at ZIVO Bioscience. Learn More on John Bernard Payne's age.
How do I contact John Bernard Payne?: The corporate mailing address for Mr. Payne and other ZIVO Bioscience executives is 2804 ORCHARD LAKE ROAD SUITE 202, KEEGO HARBOR MI, 48320. ZIVO Bioscience can also be reached via phone at (248) 452-9866 and via email at [email protected]. Learn More on John Bernard Payne's contact information.
Has John Bernard Payne been buying or selling shares of ZIVO Bioscience?: John Bernard Payne has not been actively trading shares of ZIVO Bioscience during the last quarter. Most recently, on Thursday, January 27th, John Bernard Payne bought 7 shares of ZIVO Bioscience stock. The stock was acquired at an average cost of $15.00 per share, with a total value of $105.00. Learn More on John Bernard Payne's trading history.
Who are ZIVO Bioscience's active insiders?: ZIVO Bioscience's insider roster includes Christopher Maggiore (Director), Nola Masterson (Director), and John Payne (Director). Learn More on ZIVO Bioscience's active insiders.

John Bernard Payne Insider Trading History at ZIVO Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/27/2022	Buy	7	$15.00	$105.00
1/25/2022	Buy	1,520	$15.00	$22,800.00

John Bernard Payne Buying and Selling Activity at ZIVO Bioscience

ZIVO Bioscience Company Overview

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Today's Range

Now: $20.96

$20.96

50 Day Range

MA: $18.57

$13.00

$22.00

2 Week Range

Now: $20.96

$0.48

$22.15

Volume

43 shs

Average Volume

1,569 shs

Market Capitalization

$74.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.24

Tesla Execs are Freaking Out

From Angel Publishing | Ad

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.